

## Disclosures

### Personal Commercial (29)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
American Regent	Research/Research Grants ‡ HEART FID	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Amgen Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
AstraZeneca	Research/Research Grants ‡ EXSCEL	Significant (>= \$5,000)	General Cardiology
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Bayer Corporation US	Consultant Fees/Honoraria	Modest (< \$5,000)	
Biofourmis	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Boehringer Ingelheim Pharmaceuticals, Inc	Research/Research Grants ‡ EMPACT-MI	Modest (< \$5,000)	Acute Coronary Syndromes
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	
Boston Scientific	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Bristol-Myers Squibb Company	Other - BMS acquired Myokardia and consulting via Myokardia	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
CSL Behring	Other - business lunch	Modest (< \$5,000)	Stable Ischemic Heart Disease
Cytokinetics	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Daiichi Sankyo	Research/Research Grants	Modest (< \$5,000)	General Cardiology
Eidos	Data Safety Monitoring Board	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Eli Lilly and Company	Research/Research Grants ‡ EMPACT-MI; Partnered with Boehringer Ingelheim a	None (\$0)	Heart Failure and Cardiomyopathies
Genentech, Inc	Research/Research Grants	Modest (< \$5,000)	
GlaxoSmithKline	Research/Research Grants ‡ HARMONY Outcomes	Modest (< \$5,000)	General Cardiology
Intercept Pharmaceuticals	Data Safety Monitoring Board	Modest (< \$5,000)	Other
Janssen Pharmaceuticals, Inc	Research/Research Grants ‡ ARAMIS	Modest (< \$5,000)	Other
Merck & Co., Inc.	Research/Research Grants	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Merck & Co., Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies

Myokardia	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Novartis	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Novartis	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Pfizer	Consultant Fees/Honoraria	Modest (< \$5,000)	Other
Relypsa	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Sanofi-Aventis	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
Verily	Research/Research Grants	Significant (>= \$5,000)	General Cardiology

### Personal Organizational or Other Non-Commercial (3)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
American Heart Association	Other	None (\$0)	Heart Failure and Cardiomyopathies
National Institutes of Health	Research/Research Grants ‡ NIH Collaboratory, NHLBI Heart Failure Network	None (\$0)	General Cardiology Heart Failure and Cardiomyopathies Other
PCORI	Research/Research Grants ‡ PCORnet	None (\$0)	Other

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2019	Patent dispute	Defendant ‡ Veneble Fitzpatrick	Determination of IP for a medical product	Modest (< \$5,000)

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

Certified Education Attestation | Signed on 10/18/2021

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 5/11/2021

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 5/11/2021

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/18/2021

### ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.